A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and...

Compartió un vínculo

2021-10-21 21:46:44 ·Translate ·

Le site officiel des essais cliniques a mis à jour l’étude sur le vaccin Pfizer, elle ne se termine pas le 27 septembre 2023 mais en juin 2024…
octobre 21, 2021 bertruxskydric Aucun commentaire

Source : https://clinicaltrials.gov/ct2/show/record/NCT04816643?view=record

Le site officiel des essais cliniques a mis à jour l’étude sur le vaccin Pfizer, elle ne se termine pas le 27 septembre 2023 mais en juin 2024… octobre 21, 2021 bertruxskydric Aucun commentaire Source : https://clinicaltrials.gov/ct2/show/record/NCT04816643?view=record

CLINICALTRIALS.GOV

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults - Tabular View - ClinicalTrials.gov

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults - Tabular View.

·385 Views ·0 Vista previa

Participar

Idiomas

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults - Tabular View - ClinicalTrials.gov